The purpose of this study in healthy adult males is to investigate safety and pharmacokinetics of single and multiple oral doses of KDT-3594. The purpose of this study in patients with Parkinson's disease is to investigate safety and pharmacokinetics of single and multiple oral doses of KDT-3594. The exploratory efficacy of KDT-3594 will also be investigated.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Enrollment
36
Unnamed facility
Kyushu and Other Regions, Japan
Occurrence of adverse events
Time frame: Up to 15 days after last administration
Plasma pharmacokinetic parameter of KDT-3594 and main metabolites: Cmax
Time frame: Up to 336 hours after last administration
Plasma pharmacokinetic parameter of KDT-3594 and main metabolites: AUC
Time frame: Up to 336 hours after last administration
Unified Parkinson's Disease Rating Scale (UPDRS) score (Only patient part)
Time frame: Up to 336 hours after last administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.